To make things easier, leave this box checked On shared devices, we recommend that you disconnect from Euroquity when you are done
Email

You will receive an email to define a new password

Location

Select your country

and your language

Hi ,

Welcome to your personnel profile page! Fill in your information in order to become more visible to organizations that interest you.

% completed

%

medal 1
This profile is validated by 1 label.

Company

Genome Biologics

Genome Biologics_logo
29
EQ SCORE

The EQ Score shows the company's activity and appeal on the platform: profile completeness, news, likes, follows, membership in one or more labels or communities, number of members in its network, etc.

Genome Biologics are leaders in therapeutic target discovery and RNA-targeted therapies in cardiovascular and cardiometabolic disease.

Frankfurt am Main, Stadt, Hessen, Germany

Send a message

English

Genome Biologics

English

Genome Biologics implements computational AI-driven drug identification (GENIMAPS®) to an accelerated therapeutic validation technology (GENISYST®) to more efficiently reposition EMA-approved drugs. 

In applying this novel approach, we have identified clinical and pre-clinical drugs capable of maintaining cell viability and function in the face of toxicity-induced cell death. 

The SARS-CoV-2 virus infects and kills lung and heart cells...

See more

Genome Biologics implements computational AI-driven drug identification (GENIMAPS®) to an accelerated therapeutic validation technology (GENISYST®) to more efficiently reposition EMA-approved drugs. 

In applying this novel approach, we have identified clinical and pre-clinical drugs capable of maintaining cell viability and function in the face of toxicity-induced cell death. 

The SARS-CoV-2 virus infects and kills lung and heart cells giving rise to the respiratory and cardiac issues associated with COVID-19. The pathologic pathways utilised by SARS-CoV-2 are similar to pathways induced in our disease models. 

The drug candidates we have identified specifically prevent two key aspects of COVID19 disease progression, namely the amplification of viral particles and cell death, and the induction of tissue hyperinflammation leading to adverse outcome and death in patients. 

Importantly, unlike antiviral drug strategies that may only target specific strains of SARS-CoV-2, our approach is strain agnostic as it targets underlying cellular processes that are hijacked and exploited by all SARS-CoV-2 strains to drive infection propagation and disease progression. As some of the drugs we identified are already EMA-approved, their translation to widespread patient use could be accelerated.

  • 1

    Followers

  • 1

    Like

Team member(s)

Your request has been sent
Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

European Innovation Council - Accelerator beneficiaries
This label is a guarantee for investors to discover selected companies benefiting from Business acceleration services provided by the European Commission.
167 Entities

Communities

InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
2672 Members
Access2EIC
The Access2EIC -Seal of Excellence community aims at gathering high potential European companies that received from the European Commission a “Seal of Excellence” certificate and European equity investors. https://access2eic.eu/
2140 Members

Our history

Start in 2017

  • 2017

    Genome Biologics founded Horizon2020 SME Instrument Phase 1 award

  • 2017

    Genome Biologics becomes resident of JLABS@Beerse

  • 2018

    Genome Biologics wins Horizon 2020 SME Phase 2 award €2.4M

  • 2018

    Merck Venture Lounge Winner

  • 2019

    Investment secured for first CVD asset €10M milestone payment

to be continued ...